Lockport, NY – January 3, 2023 – VanDeMark, a leading global producer of life science chemistries, today announced the appointment of Jim Elliott as Chief Executive Officer effective immediately. Mr. Elliott succeeds Jeff Davis, who has stepped down from his role.
“We look forward to continuing VanDeMark’s growth trajectory under the leadership of Jim Elliott. This is an exciting time for the Company as we continue to build upon VanDeMark’s strong foundation, expand product and service offerings, and drive growth in the life science markets. Jim’s proven track record and more than 20 years of chemical industry experience make him an excellent leader for the Company,” said Randy Dearth, Senior Director at SK Capital. “On behalf of VanDeMark’s Board of Directors, I’d like to thank Jeff Davis for his leadership, commitment, and valuable contributions to VanDeMark during his time with the Company. Thanks to his contributions, VanDeMark has a strong foundation in place.”
“I am excited for the opportunity to work with the VanDeMark team to drive its next chapter of growth,” said Mr. Elliott. “I look forward to working in partnership with SK Capital, Comvest Partners, and our VanDeMark colleagues to help the Company reach its full potential and drive value to customers around the globe.”
Mr. Elliott most recently served as the Vice President and General Manager of the Performance Materials business at Vertellus, an Indianapolis-based global specialty chemical business. Previously, he spent seven years at Dow Silicones where he held several global strategic marketing roles. Mr. Elliott holds a Bachelor of Science degree in Chemistry from Eastern Illinois University and an MBA from Xavier University.
Headquartered in Lockport, N.Y., with a facility in Kazincbarcika, Hungary, VanDeMark is recognized as a worldwide leader in the production of high-end specialty chemical intermediates and derivatives for a diverse set of end markets including life sciences, electronics, polymers, coatings, personal care, and flavor & fragrances. The Company differentiates itself with a comprehensive portfolio of value-added building blocks and intermediates primarily used in life science applications. With expertise in product research and development, process optimization, quality assurance and control, regulatory guidance, and the production of fine phosgene derivatives, the Company also offers custom manufacturing capabilities for global customers who view VanDeMark as a critical provider of specialty building blocks based on phosgene and other chemistries. For more than 70 years, VanDeMark has served as a trusted partner for customers by providing exceptional service and high-quality products. The Company operates manufacturing locations in North America and Europe and employs approximately 200 people. For more information, please visit www.vandemark.com.